Resumen de Optobionics corporation.

• Focuses on the development by Optobionics Corporation of a retinal implant microchip to treat macular degeneration. Thirty million people worldwide are afflicted with age-related macular degeneration and retinitis pigmentosa, two potentially debilitating eye diseases for which there is no cure. By crippling the retina's ability to sense and process light, the conditions can make a patient's world go from blurry to black. Clinical trial results published this past April confirmed that a microchip developed by Optobionics that is implanted under the retina resulted in significant visual improvement with virtually no adverse side effects. Designed by brothers Vincent and Alan Chow, the chip emits electrochemical impulses to stimulate the remaining healthy retinal cells.